[go: up one dir, main page]

CL2017002065A1 - Proteasas de cisteína - Google Patents

Proteasas de cisteína

Info

Publication number
CL2017002065A1
CL2017002065A1 CL2017002065A CL2017002065A CL2017002065A1 CL 2017002065 A1 CL2017002065 A1 CL 2017002065A1 CL 2017002065 A CL2017002065 A CL 2017002065A CL 2017002065 A CL2017002065 A CL 2017002065A CL 2017002065 A1 CL2017002065 A1 CL 2017002065A1
Authority
CL
Chile
Prior art keywords
cysteine proteases
methods
polypeptide
vvo
lgg
Prior art date
Application number
CL2017002065A
Other languages
English (en)
Inventor
Christian Kjellman
Sofia Jarnum
Emma Nordahl
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of CL2017002065A1 publication Critical patent/CL2017002065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

<p>La presente invención se refiere a un polipéptido novedoso qua exhibe actividad de proteasa de cisteina de lgG y usos in vivo y ex vvo de Ins mismos. Usos del polipéptido incluyen métodos para la prevención o tratamiento de enfermedades y alecciones mediadas por IgG, y métodos para el análisis de 19G.</p>
CL2017002065A 2015-02-12 2017-08-11 Proteasas de cisteína CL2017002065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein

Publications (1)

Publication Number Publication Date
CL2017002065A1 true CL2017002065A1 (es) 2018-04-02

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002065A CL2017002065A1 (es) 2015-02-12 2017-08-11 Proteasas de cisteína

Country Status (23)

Country Link
US (5) US10696959B2 (es)
EP (2) EP3256580B1 (es)
JP (1) JP6961486B2 (es)
KR (1) KR102524613B1 (es)
CN (2) CN107532156A (es)
AU (2) AU2016217800B2 (es)
BR (1) BR112017017284A2 (es)
CA (1) CA2976003A1 (es)
CL (1) CL2017002065A1 (es)
CO (1) CO2017009061A2 (es)
DK (1) DK3256580T3 (es)
EA (1) EA035130B1 (es)
ES (1) ES2927234T3 (es)
GB (1) GB201502306D0 (es)
IL (1) IL253938B (es)
LT (1) LT3256580T (es)
MX (1) MX390806B (es)
MY (1) MY188696A (es)
PL (1) PL3256580T3 (es)
PT (1) PT3256580T (es)
SG (1) SG11201706346QA (es)
WO (1) WO2016128558A1 (es)
ZA (1) ZA201705113B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
AU2020398125C1 (en) 2019-12-06 2023-05-11 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
CN115151648A (zh) 2020-02-14 2022-10-04 阿尔特拉吉尼克斯制药公司 用于治疗cdkl5缺陷障碍的基因疗法
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
JP7795790B2 (ja) 2020-06-05 2026-01-08 上海宝済薬業股▲ふん▼有限公司 酵素とウィルスとの薬物組成物及びその使用
EP4169934A4 (en) * 2020-06-18 2024-07-24 Shanghai Bao Pharmaceuticals Co., Ltd. IMMUNOGLOBULIN DEGRADATION ENZYME MUTANT IDEA
BR112023003145A2 (pt) 2020-08-19 2023-05-09 Sarepta Therapeutics Inc Vetores de vírus adenoassociado para tratamento da síndrome de rett
AU2021358957A1 (en) 2020-10-07 2023-06-08 AskBio Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
JP2024544565A (ja) 2021-11-15 2024-12-03 ハンサ バイオファーマ エービー 養子細胞移入免疫療法を増強する方法
EP4450081A4 (en) 2021-12-16 2025-05-07 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin-degrading enzyme-fermented FC variant
TW202334183A (zh) 2021-12-22 2023-09-01 大陸商上海寶濟藥業有限公司 免疫球蛋白降解酶ｌｄｅＥ的突變體的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2789252C (en) 2000-12-21 2016-11-15 Id Biomedical Corporation Of Quebec Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1576964A4 (en) * 2002-11-29 2008-06-11 Morinaga Milk Industry Co Ltd PROTEASE INHIBITOR
SI1601770T1 (sl) * 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
PL1901773T3 (pl) * 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
US7544577B2 (en) * 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
CN101889082A (zh) 2007-09-14 2010-11-17 季诺维斯公司 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒
CN102026658A (zh) * 2007-12-13 2011-04-20 英特瓦克公司 改进的免疫组合物
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
CA2750977A1 (en) 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
CA2799136A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Also Published As

Publication number Publication date
US11667905B2 (en) 2023-06-06
SG11201706346QA (en) 2017-09-28
AU2016217800B2 (en) 2021-08-12
KR102524613B1 (ko) 2023-04-21
DK3256580T3 (en) 2022-10-03
IL253938A0 (en) 2017-10-31
US20250304937A1 (en) 2025-10-02
EP3256580B1 (en) 2022-07-06
EA035130B1 (ru) 2020-04-30
CN107532156A (zh) 2018-01-02
IL253938B (en) 2020-01-30
ES2927234T3 (es) 2022-11-03
US10696959B2 (en) 2020-06-30
US20230357741A1 (en) 2023-11-09
PL3256580T3 (pl) 2022-11-28
EP3256580A1 (en) 2017-12-20
KR20170116137A (ko) 2017-10-18
WO2016128558A1 (en) 2016-08-18
CN114231512A (zh) 2022-03-25
LT3256580T (lt) 2022-10-10
NZ733959A (en) 2024-07-26
ZA201705113B (en) 2024-01-31
GB201502306D0 (en) 2015-04-01
JP2018506286A (ja) 2018-03-08
US20200283749A1 (en) 2020-09-10
PT3256580T (pt) 2022-10-03
US12359183B2 (en) 2025-07-15
EP4108768A1 (en) 2022-12-28
CO2017009061A2 (es) 2018-01-16
JP6961486B2 (ja) 2021-11-05
AU2016217800A1 (en) 2017-08-10
CN114231512B (zh) 2025-02-14
US20180023070A1 (en) 2018-01-25
US20220170004A1 (en) 2022-06-02
MX390806B (es) 2025-03-21
MY188696A (en) 2021-12-23
MX2017010390A (es) 2017-12-07
AU2021266293B2 (en) 2024-10-03
AU2021266293A1 (en) 2021-12-09
CA2976003A1 (en) 2016-08-18
US11214784B2 (en) 2022-01-04
BR112017017284A2 (pt) 2018-04-17
EA201791773A1 (ru) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2017002065A1 (es) Proteasas de cisteína
ZA201705114B (en) Cysteine protease
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UY36701A (es) Tratamiento contra el cáncer por manipulación de la microflora comensal
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
PH12018500578A1 (en) Methods of treating inflammatory diseases
DK3542635T3 (da) Valleproteinbaseret yoghurtlignende produkt med højt proteinindhold, ingrediens egnet til fremstilling deraf og fremgangsmåde til fremstilling.
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
MX2017000169A (es) Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue.
MX2017002469A (es) Composiciones de matrices extracelulares.
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
HUE057044T2 (hu) Sejt- vagy szövetnekrózis kezelésére és/vagy megelõzésére szolgáló, katepszin C-t és/vagy CELA1-et és/vagy CELA3A-t és/vagy szerkezetileg rokon enzimeket specifikusan targetáló készítmények
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
EP3192368C0 (en) COMPOSITION FOR THE PRESERVATION OF CELLS, CONTAINING, AS ACTIVE INGREDIENTS, RECOMBINANT HUMAN SERUM ALBUMIN DERIVED FROM A PLANT AND PLANT PEPTIDES
MX383460B (es) Derivados peptidicos novedosos y sus usos.
MX380802B (es) Un proceso de etapas múltiples para la producción de no.
DK3270950T3 (da) Isolerede peptider og fragmenter deraf fra fibrinogen til anvendelse som lægemidler, især ved inflammatoriske hudsygdomme